Effects on climacteric symptoms, bone and lipoprotein metabolism of hormone replacement therapy delivered by estradiol-releasing intravaginal rings: a pilot study

References

• Peck WA, Burckhardt P, Christiansen C, et al. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646–50
   Google Scholar
• Grodstein F, Stampfer MJ. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199–210
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D. Hormone replace-ment therapy, heart disease, and other con-siderations. Annu Rev Public Health 1998;19: 55–72
   Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initia-tive randomized controlled trial. J Am Med Assoc 2002;288:321–33
   Google Scholar
• Cardozo LD. Routes of oestrogen administra-tion. In Studd JWW, Whitehead MI, eds. The Menopause. London: Blackwell Scientific Publications, 1988:138–45
   Google Scholar
• Ganger K, Cust M, Whitehead MI. Symptoms of oestrogen deficiency associated with supra-physiological plasma oestradiol concentrations in women with oestradiol implants. Br Med J 1989;299:601–2
   Google Scholar
• Englund DE, Victor A, Johansson EDB. Pharmacokinetics and pharmacodynamic effects of vaginal oestradiol administration from silastic rings in postmenopausal women. Maturitas 1981;3:125–33
   Google Scholar
• Stumpf PG, Maruca J, Santen RJ, et al. Development of a vaginal ring for achieving physiologic levels of 170-estradiol in hypo-estrogenic women. J Clin Endocrinol Me tab 1982;54:208–30
   PubMed Web of Science ®Google Scholar
• Stumpf PG. Selecting serum estradiol levels achieved by vaginal rings. Obstet Gynecol 1986; 67:91–4
   PubMed Web of Science ®Google Scholar
• Vartiainen J, Wahlstrom T, Nilsson C-G. Effects and acceptability of a new 170-oestradiol-releasing vaginal ring in the treatment of post-menopausal complaints. Maturitas 1993;17: 129–37
   Google Scholar
• Nash HA, Brache V, Alvarez-Sanchez F, et al. Estradiol delivery by vaginal rings: potential for hormone replacement therapy. Maturitas 1997;26:27–33
   Google Scholar
• Henriksson L, Stjernquist M, Boquist L, et al. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 1994;171:624–32
   PubMed Web of Science ®Google Scholar
• Henriksson L, Stjernquist M, Boquist L, et al. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmeno-pausal women with symptoms and signs of urogenital ageing. Am J Obstet Gynecol 1996; 174:85–92
   PubMed Web of Science ®Google Scholar
• Woolfson AD, Elliott GRE, Gilligan CA, et al. Design of an intravaginal ring for the controlled delivery of 170-estradiol as its 3-acetate ester. J Controlled Release 1999;61:319–28
   PubMed Web of Science ®Google Scholar
• Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29:25–31
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Barnes JF, Farish E. A rapid semi-micro method for the separation of lipoprotein fractions that uses a benchtop ultracentrifuge. Clin Chim Acta 1994;226:95–9
   Google Scholar
• McDowell IF, McEneny J, Trimble ER. A rapid method for measurement of the susceptibility to oxidation of low-density lipoprotein. Ann Clin Biochem 1995;32:167–74
   Google Scholar
• Nash HA, Alvarez-Sanchez F, Mishell DR, et al. Estradiol-delivering vaginal rings for hormone replacement therapy. Am J Obstet Gynecol1999; 181:1400–6
   PubMed Web of Science ®Google Scholar
• Wiklund I, Karlberg J, Mattson L-A. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993;168:824–30
   Google Scholar
• Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy — a placebo controlled study. Int J Fertil 1995;40:73–8
   Google Scholar
• Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615–20
   PubMed Web of Science ®Google Scholar
• Crook D, Cust MP, Gangar KF, et al. Compari-son of transdermal and oral estrogen—progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166: 950–5
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Farish E, Hart DM, et al. Long-term implant therapy — effects on lipoproteins and steroid levels in postmenopausal women. Acta Endocrinol 1986;111:419–23
   PubMedGoogle Scholar
• Lapidus L, Bengtsson C, Lindquist O, et al. Triglycerides — main lipid risk factor for cardio-vascular disease in women? Acta Med Scand 1985;217:481–9
   PubMed Web of Science ®Google Scholar
• Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultra-low doses crinol Metab 2001;86:2757–62
   Google Scholar
• Steinberg D, Parathasarthy S, Carew TE, et al.
   Google Scholar
• Witztum JL, Steinberg D. Role of oxidised low
   Google Scholar
• Sack MN, Rader DJ, Cannon RO III. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994;343:269–70
   Google Scholar
• Guetta V, Panza JA, Waclawiw MA, et al.
   Google Scholar
• McManus J, McEneny J, Thompson W, et al. The effect of hormone replacement therapy on the
   Google Scholar
• Penis P, Alvarez L, Monegal A, et al. Biochemical markers of bone turnover after surgical meno-
   Google Scholar
• Rosen CJ, Chesnut CH III, Mallinak NJS. The predictive value of biochemical markers of bone
   Google Scholar
• Lindsay R. The role of estrogen in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998;27:399–409
   PubMed Web of Science ®Google Scholar
• Lindsay R, Hart DM, Clark DM. The minimum effective dose of oestrogen for prevention of post-menopausal bone loss. Obstet Gynecol 1984;63: 759–63
   Google Scholar
• Christiansen C, Christiansen MS, Larsen N-E, et al. Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose—response relationships in early postmenopausal women. J Clin Endocrinol Metab 1982;55: 1124–30
   Google Scholar
• Field CS, Ory SJ, Wahner HW, et al. Preventive effects of transdermal 170-estradiol on osteo-porotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 1993;168:114–21
   PubMed Web of Science ®Google Scholar
• Gass M, Liu J, Rebar RW. The effect of low-dose conjugated equine estrogens and cyclic MPA on bone density. Maturitas 2002;41:143–7
   Google Scholar
• Gambacciani M, Monteleone P, Genazzani AR. Low-dose hormone replacement therapy: effects on bone. Climacteric 2002;5:135–9
   Google Scholar
• Evans SF, Davie MW. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all postmenopausal ages. Clin Endocrinol 1996;44: 79–84
   PubMed Web of Science ®Google Scholar
• Selby PL, Peacock M. Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women. Br Med J 1986;293:1337–9
   PubMed Web of Science ®Google Scholar
• Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17P-estradiol. Am J Obstet Gynecol 1997;177: 115–19
   Google Scholar